Turnaround time for COVID-19 test results

^一種COVID-19 antibody test and vaccination: Positive results may also occur after a COVID-19 vaccination, but the clinical significance is not yet known. It is also not known how good this test is at detecting antibodies in those who have been vaccinated.

Keep in mind that tests for priority patients are processed ahead of tests for all other patients. Priority patients include hospitalized patients, individuals in long-term care (such as nursing homes), and presurgical patients.

Important information about COVID-19 antibody testing

這種Covid-19抗體測試可以檢測來自先前或最近感染的抗體，無論是否存在症狀。陽性結果也可能發生在Covid-19疫苗接種後，但臨床意義尚不清楚，也不知道該測試在檢測已接種疫苗的人中的抗體是多麼好。或者，核衣殼測試隻能檢測來自先前或最近感染的抗體。

自然感染後,目前的研究顯示that it may be best to get antibody testing 3 to 4 weeks after symptom onset or known exposure to COVID-19 to increase the opportunity to detect an immune response.

一種fter vaccination, it is not yet known how long it takes to develop antibodies. Antibody testing for the purposes of vaccine decision-making is not currently recommended by theCDC。

如果您的測試得太快，您的身體可能沒有產生足夠的抗體來檢測到測試，這可能導致假陰性結果。該測試有時可以檢測來自其他相關冠狀蟲病毒的抗體，您可能已經暴露於導致常見感冒的病毒。這可能導致錯誤的陽性結果。

This test should not be used to diagnose an active COVID-19 infection. If an active infection is suspected, molecular or antigen testing is recommended. Learn more about ourQuestDirect COVID-19 Active Infection Test。

一種negative抗體試驗結果意味著在血液樣品中未檢測到抗體。這可能有幾種可能的含義。它可能意味著：

• You have not been infected with SARS-CoV-2, or
• You have been infected with SARS-CoV-2, but your antibodies have not reached a sufficient level for the test to be able to detect them, or
• 您已被SARS-COV-2感染，但在某人感染後，有時更長的抗體可能需要足夠的時間進行抗體的抗體（它最多需要1至3周。

一種positive一種ntibody test result means that antibodies were detected in your blood sample. This can have a couple of possible meanings. It could mean that:

• 您已在過去的某些時候感染了SARS-COV-2，或者
• Uncommonly, you may have developed antibodies from an earlier infection with a different virus related to SARS-CoV-2 and the laboratory test cannot distinguish between these other virus antibodies and those antibodies generated in response to SARS-CoV-2.

了解更多一種bout theCDC的抗體測試指南。

COVID-19 testing statements

• The antibody tests, molecular tests, and antigen tests (together “All tests”) have not been FDA cleared or approved;
• 所有測試已由FDA授權歐盟以授權實驗室使用;
• 抗體試驗僅授權用於檢測針對SARS-COV-2的IgG抗體，而不是任何其他病毒或病原體;
• The COVID-19 molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens;
• The COVID-19 and Flu test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, and influenza B virus, and not for any other viruses or pathogens; and
• Covid-19，流感和RSV測試僅針對來自SARS-COV-2，流感A，流感B和呼吸合胞病毒（RSV）的核酸同時定性檢測和分化，而不是任何其他病毒或病原體;
• The antigen tests have been authorized only for the detection of proteins from SARS-CoV-2, and not for any other viruses or pathogens; and
• 一種ll tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

一種bout the FDA Emergency Use Authorization (EUA) Status

This test has been authorized by the FDA under an Emergency Use Authorization (EUA). This means that while Quest Diagnostics has validated the test and has the data to believe the test and the collection kit are accurate, this test has not been FDA cleared or approved; This test has been authorized by FDA under an EUA for use by authorized laboratories; this test has been authorized only for the detection of IgG Antibodies against SARS-CoV-2, not for any other viruses or pathogens; and, this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use on in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(B)(1) of the Act, 21 U.S.C. § 360BBB-3(B)(1), unless the authorization is terminated or revoked sooner. Additional studies need to be conducted for this test and others like it to be FDA cleared or approved.